Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Designing and incorporating a real world data approach to international drug development and use: what the UK offers
Andrew Bate, Jane Juniper, Andy Lawton, et al.
Drug Discovery Today (2015) Vol. 21, Iss. 3, pp. 400-405
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Biomedical applications of mRNA nanomedicine
Qingqing Xiong, Gha Young Lee, Jianxun Ding, et al.
Nano Research (2018) Vol. 11, Iss. 10, pp. 5281-5309
Open Access | Times Cited: 111
Ethics and Epistemology in Big Data Research
Wendy Lipworth, Paul H. Mason, Ian Kerridge, et al.
Journal of Bioethical Inquiry (2017) Vol. 14, Iss. 4, pp. 489-500
Closed Access | Times Cited: 96
From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources
Gianluca Trifirò, Janet Sultana, Andrew Bate
Drug Safety (2017) Vol. 41, Iss. 2, pp. 143-149
Closed Access | Times Cited: 68
Innovation at the Intersection of Clinical Trials and Real‐World Data Science to Advance Patient Care
Brandon Swift, Lokesh Jain, Craig White, et al.
Clinical and Translational Science (2018) Vol. 11, Iss. 5, pp. 450-460
Open Access | Times Cited: 51
Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019
Sini Marika Eskola, Hubertus G.M. Leufkens, Andrew Bate, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 1, pp. 310-320
Open Access | Times Cited: 38
Leveraging Big Data to Transform Drug Discovery
Benjamin S. Glicksberg, Li Li, Rong Chen, et al.
Methods in molecular biology (2019), pp. 91-118
Open Access | Times Cited: 37
Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance
Andrew Bate, Ken Hornbuckle, Juhaeri Juhaeri, et al.
Therapeutic Advances in Drug Safety (2019) Vol. 10
Open Access | Times Cited: 34
Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications
Zuanji Liang, Yunfeng Lai, Meng Li, et al.
Chinese Medicine (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 27
Real‐World Data and Real‐World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIII
Sean Hennessy, Yoshiko Atsuta, Staci Hill, et al.
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 3
Open Access
Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer
Wenjun Chen, Daming Kong, Liang Li
Asian Journal of Andrology (2020) Vol. 23, Iss. 2, pp. 163-169
Open Access | Times Cited: 24
Machine Learning in Causal Inference: Application in Pharmacovigilance
Yiqing Zhao, Yue Yu, Hanyin Wang, et al.
Drug Safety (2022) Vol. 45, Iss. 5, pp. 459-476
Open Access | Times Cited: 15
An industry perspective on the use of machine learning in drug and vaccine safety
Jeffery L. Painter, Raymond Kassekert, Andrew Bate
Frontiers in Drug Safety and Regulation (2023) Vol. 3
Open Access | Times Cited: 9
Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid
Paul A. Dickinson, Filippos Kesisoglou, Talia Flanagan, et al.
Journal of Pharmaceutical Sciences (2016) Vol. 105, Iss. 11, pp. 3243-3255
Open Access | Times Cited: 24
Real-World Data for the Drug Development in the Digital Era
Xianchen Liu
Journal of Artificial Intelligence and Technology (2022)
Open Access | Times Cited: 14
Safety of medicines and vaccines – building next generation capability
Andrew Bate, Jens‐Ulrich Stegmann
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 12, pp. 1051-1063
Open Access | Times Cited: 17
Use of Real-World Data for the Research, Development, and Evaluation of Oncology Precision Medicines
Jan Lewis, Ian Kerridge, Wendy Lipworth
JCO Precision Oncology (2017), Iss. 1, pp. 1-11
Open Access | Times Cited: 20
Advancing the Regulation of Traditional and Complementary Medicine Products: A Comparison of Five Regulatory Systems on Traditional Medicines with a Long History of Use
Zuanji Liang, Hao Hu, Junlei Li, et al.
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-16
Open Access | Times Cited: 16
Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact
Andrew Bate
Pharmacoepidemiology and Drug Safety (2017) Vol. 26, Iss. 9, pp. 1013-1017
Closed Access | Times Cited: 14
World bleeding disorders registry: The pilot study
Donna Coffin, Caroline Herr, Jamie O’Hara, et al.
Haemophilia (2018) Vol. 24, Iss. 3
Open Access | Times Cited: 14
Real-world data: from planning to analysis
Alexander Solodovnikov, E. Yu. Sorokina, T.A. Goldina
Medical Technologies Assessment and Choice (2020) Vol. 41, Iss. 3, pp. 9-9
Open Access | Times Cited: 11
Lessons from meta‐analyses of randomized clinical trials for analysis of distributed networks of observational databases
Andrew Bate, Christy Chuang‐Stein, Andrew Roddam, et al.
Pharmaceutical Statistics (2018) Vol. 18, Iss. 1, pp. 65-77
Open Access | Times Cited: 10
Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy
Ylenia Ingrasciotta, Janet Sultana, Ursula Kirchmayer, et al.
BioDrugs (2019) Vol. 33, Iss. 4, pp. 345-352
Closed Access | Times Cited: 8
Digital biomarkers for post-licensure safety monitoring
Luis Garcia‐Gancedo, Andrew Bate
Drug Discovery Today (2022) Vol. 27, Iss. 11, pp. 103354-103354
Open Access | Times Cited: 5
Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer
Wenjun Chen, Liang Li, Shuangmin Ji, et al.
European Journal of Clinical Pharmacology (2020) Vol. 76, Iss. 4, pp. 589-601
Closed Access | Times Cited: 6
What can real world evidence contribute to regulatory science in pre and post marketing setting?
N. Martini, J. Sultana, Addis, et al.
(2020) Vol. 02, Iss. 02
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top